NanoViricides Set to Present at PODD 2025 Conference

On October 27, 2025, NanoViricides, Inc. is scheduled to present at the PODD 2025 Conference in Boston. Anil R. Diwan, PhD, the company's President, will discuss their drug pipeline and platform technologies available for licensing. A primary focus is NV-387, a clinical stage drug candidate advancing into Phase II trials for treating MPOX in the Democratic Republic of Congo.

NV-387 shows promise as a broad-spectrum antiviral, notably against RSV, Influenza A, and Coronaviruses. It is positioned as a potential first-line therapy for various respiratory viral infections. The drug's mechanism mimics sulfated proteoglycans, crucial for virus binding, offering a resilient approach against viral evolution.

NanoViricides' technology also extends to a pan-herpesvirus candidate, NV-HHV-1, and an anti-HIV candidate, NV-HIV-1, with both showing promising preclinical results.